For the Bristol Myers Squibb (BMS) treasury function, innovation has long been fundamental. Still, after integrating with ...
Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...
Bristol Myers Squibb will make even deeper cuts to its organization to enhance efficiencies as it faces the 2028 loss of ...
Bristol Myers Squibb has bolstered its case for Opdivo to be used as a pre-operative treatment for non-small cell lung cancer ...
The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as ...
Genna Biddell will oversee development of the London P&C reinsurance business, working with teams across the US, London and ...
US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) ...
Leonardo DRS, a US subsidiary of the Italian group, has secured a contract worth USD7 million to deliver its battle ...
BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics towards the end of 2023, and analysts at ...
Quality LiFePO4 battery featuring long cycle life and smart BMS, perfect for various applications with reliable performance.
Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab ...
BMS Group has announced the appointment of Kris Westall as Chief Operating Officer (COO) of BMS Re US, effective immediately.